Behavioral epigenetic therapy
for cognitive
and neurodegenerative disease

Novel antibiotics –
Sold to AstraZeneca
(NYSE: AZN) Mar 2010

Novel antibodies for immuno-
oncology – Sold to Novartis
(NYSE: NVS) Feb 2014

Cancer therapeutics and
diagnostics – Sold to Amgen
(NASDAQ: AMGN) Jan 2012

First-in-class
RNA therapies
for severe genetic diseases

Novel therapeutics using proprietary
computational chemistry –
IPO Sept 2014 (NASDAQ: VTAE)

Migraine prevention therapy –
Sold to Eli Lilly (NYSE: LLY)
Dec 2013

Next-generation oncolytic
immunotherapies for
cancer treatment

Anti-viral therapies –
Sold to AstraZeneca
(NYSE: AZN) Feb 2007

Cancer immunotherapies
at the interface of
innate & adaptive immunity

Universal
cell-based
cancer immunotherapy

Innovative
micro-RNA-based
therapies

Novel anesthetics –
Sold to The Medicines Company
(NASDAQ: MDCO) Jan 2015

Novel vaccine platform –
Sold to Johnson & Johnson
(NYSE: JNJ) Oct 2010

Covalent irreversible
inhibitors – Sold to Celgene
(NASDAQ: CELG) Jan 2012

Novel cancer drugs using
combinatorial chemistry –
IPO Oct 1996 (NASDAQ: ARQL)

RNAi-based drugs for
severe diseases – IPO
Jun 2004 (NASDAQ: ALNY)

New class of
regulated cell and
gene therapies

Novel bicyclic peptides (bicycles)
and bicycle drug conjugates
for cancer

First-in-class therapies for severe
obesity and rare genetic conditions –
IPO June 2014 (NASDAQ: ZFGN)

Development of complex
biopharma products – IPO
Jun 2004 (NASDAQ: MNTA)

Proprietary pharmaceuticals
for neonatal care
and pediatrics

Novel fibrosis therapeutic –
Sold to Biogen Idec
(NASDAQ: BIIB) Feb 2012

Genetic analysis to find novel
drug targets – Sold to Amgen
(NASDAQ: AMGN) Dec 2012

Novel therapeutics for
schizophrenia and other
severe psychiatric diseases

Cancer therapeutics
targeting anabolic
tumor metabolism

Discovering new medicines
for severe
neurodegenerative diseases

Next generation
synthetic biology platform
for novel therapeutics

Novel therapeutics
targeting
diseases of aging

Precision gene editing to
cure severe diseases –
IPO May 2016 (NASDAQ: NTLA)

Bispecific antibodies
to improve the treatment
of serious diseases

World-class antibody
discovery platform – IPO
Mar 1999 (XETRA: MOR.DE)

Utilizing the innate immune
system to treat cancer and
inflammatory diseases

Novel medicines for auto-
immune diseases – Sold to
BMS (NYSE:BMY) Mar 2016

Novel therapies
for severe, highly drug-resistant
bacterial infections

Novel biologic
therapeutics for
autoimmune diseases

Specialty pharma focused on
chronic inflammatory diseases –
IPO July 2011 (NASDAQ: HZNP)

Breakthrough computer-aided
drug design
for transformative medicines

Mouse platforms
for the generation of
fully human antibodies

Genomics-based cancer
drug discovery – IPO
Apr 2000 (NASDAQ: EXEL)

Minimally invasive
heart valve
devices

Therapies for rare,
debilitating, and underserved
neurological diseases

Small molecule
drug design
using statistical modeling

Human antibody therapies for
oncology – Sold to Daiichi
Sankyo (TYO: 4568) May 2008

Therapies for severe
cardiovascular diseases –
IPO Apr 2000 (SWX: ATLN)

Cell and gene therapies
for rare diseases
and cancer

Biomarker-guided therapies
for chronic pain
and inflammation

Novel bio-therapies –
Sold to Bristol-Myers Squibb
(NYSE: BMY) Oct 2007

Tamper resistant therapies for
chronic pain – IPO Feb 2014
(NASDAQ: EGLT)